MX354256B - Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos. - Google Patents

Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos.

Info

Publication number
MX354256B
MX354256B MX2012009228A MX2012009228A MX354256B MX 354256 B MX354256 B MX 354256B MX 2012009228 A MX2012009228 A MX 2012009228A MX 2012009228 A MX2012009228 A MX 2012009228A MX 354256 B MX354256 B MX 354256B
Authority
MX
Mexico
Prior art keywords
agents
dibenzosuberone
xanthene
acridine
fluorene
Prior art date
Application number
MX2012009228A
Other languages
English (en)
Inventor
M Cholody Wieslaw
zang Yi
Zuck Karina
W H Watthey Jeffrey
Ohler Zoe
Strovel Jeffrey
Ohler Gene
Chellappan Sheela
Padia Janak
Original Assignee
Avalon Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals filed Critical Avalon Pharmaceuticals
Publication of MX354256B publication Critical patent/MX354256B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)

Abstract

Se presentan agentes químicos, como por ejemplo derivados de disulfonamida de fluoreno, antraceno, xanteno, dibenzosuberona, y acridina, y estructuras de anillos heterocíclicos similares, incluyendo sus sales, que actúan como agentes anticáncer y antitumor, especialmente cuando tales agentes modulan la actividad de la vía de señalización Wnt/ß-catenina, y sirven para reducir los niveles de ß-catenina presentes en células, como por ejemplo células cancerosas, o en donde los agentes modulan los niveles de expresión génica en sistemas celulares, incluyendo células cancerosas, junto con métodos para la preparación de tales agentes, así como composiciones farmacéuticas que contienen tales agentes como ingredientes activos y métodos para su utilización como agentes terapéuticos.
MX2012009228A 2007-05-10 2008-05-09 Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos. MX354256B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92859207P 2007-05-10 2007-05-10
US99915307P 2007-10-15 2007-10-15
PCT/US2008/006015 WO2008140792A1 (en) 2007-05-10 2008-05-09 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

Publications (1)

Publication Number Publication Date
MX354256B true MX354256B (es) 2018-02-20

Family

ID=40002552

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012009228A MX354256B (es) 2007-05-10 2008-05-09 Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos.
MX2009011970A MX2009011970A (es) 2007-05-10 2008-05-09 Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009011970A MX2009011970A (es) 2007-05-10 2008-05-09 Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos.

Country Status (17)

Country Link
US (3) US8129519B2 (es)
EP (1) EP2152258B1 (es)
JP (2) JP5782586B2 (es)
KR (1) KR101486026B1 (es)
CN (2) CN101730531A (es)
AU (1) AU2008251800B2 (es)
CA (2) CA2871493C (es)
DK (1) DK2152258T3 (es)
ES (1) ES2584188T3 (es)
HU (1) HUE029155T2 (es)
IL (2) IL202039A (es)
MX (2) MX354256B (es)
NZ (2) NZ597731A (es)
PL (1) PL2152258T3 (es)
PT (1) PT2152258T (es)
WO (1) WO2008140792A1 (es)
ZA (1) ZA200907859B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101486026B1 (ko) * 2007-05-10 2015-01-22 도그우드 파마슈티컬스, 아이엔씨. 플루오렌, 안트라센, 잔텐, 디벤조수베론 및 아크리딘의 유도체 및 이의 용도
US8466149B2 (en) * 2007-08-15 2013-06-18 Merck Sharp & Dohme Corp. 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I
ES2835553T3 (es) 2009-08-10 2021-06-22 Biosplice Therapeutics Inc Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
KR101161290B1 (ko) 2009-10-16 2012-07-02 에스에프씨 주식회사 축합방향족화합물 및 이를 이용한 유기전계발광소자
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
HUE041576T2 (hu) 2011-09-14 2019-05-28 Samumed Llc Indazol-3-karboxamid-származékok és alkalmazásuk Wnt/b-katenin szignalizáló útvonal inhibitorokként
EA027770B1 (ru) * 2011-11-06 2017-08-31 БЕТА КЭТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ПРИМЕНЕНИЕ ИНГИБИТОРА Wnt/β-КАТЕНИНОВОГО МЕХАНИЗМА ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЯ И РАССТРОЙСТВА, СВЯЗАННОГО С АКТИВНОСТЬЮ ТРАНСДУЦИН β-ПОДОБНОГО БЕЛКА 1 (TBL1), ПРЕДСТАВЛЯЮЩЕГО СОБОЙ МИЕЛОПРОЛИФЕРАТИВНУЮ НЕОПЛАЗИЮ ИЛИ ХРОНИЧЕСКИЙ МИЕЛОИДНЫЙ ЛЕЙКОЗ
WO2013071232A1 (en) * 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
SG11201407148XA (en) 2012-05-04 2014-11-27 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US9908867B2 (en) 2013-01-08 2018-03-06 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
US11610644B2 (en) * 2014-10-24 2023-03-21 Koninklijke Philips N.V. Superior bioinformatics process for identifying at risk subject populations
EP3328819B1 (en) * 2015-07-28 2020-04-01 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compounds prodrugs and their uses
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017058716A1 (en) * 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Tricyclic compounds
WO2017079759A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
MY199242A (en) 2016-06-01 2023-10-22 Samumed Llc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
CN106106481B (zh) * 2016-06-16 2019-06-28 湖北工业大学 一种棉铃虫甾醇载体蛋白2抑制剂及其虚拟筛选方法
BR112019008061A2 (pt) 2016-10-21 2019-09-17 Samumed Llc métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
WO2018118711A1 (en) 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Small molecule ferroptosis inducers
EP4656191A1 (en) 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
US11266637B2 (en) * 2018-06-01 2022-03-08 Iterion Therapeutics, Inc. Formulations of tegavivint and related compounds
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
US11136307B1 (en) * 2020-09-29 2021-10-05 Iterion Therapeutics, Inc. Crystalline form of tegavivint, method of preparation, and use thereof
US11571388B2 (en) 2020-11-24 2023-02-07 Iterion Therapeutics, Inc. Lyophilized formulations of tegavivint
CN117567385B (zh) * 2023-11-23 2024-04-30 中国人民解放军军事科学院军事医学研究院 一种靶向clec5a的小分子抑制剂及其应用
CN119409635B (zh) * 2024-11-04 2026-01-09 河南师范大学 具有抗癌活性的氟代甲基取代茚并[1,2-b]吡啶类化合物及其合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983248A (en) 1968-11-21 1976-09-28 Richardson-Merrell Inc. Bis(aminoalkylsulfamoyl)anthraquinone antiviral agents
US3627791A (en) * 1968-11-21 1971-12-14 Richardson Merrell Inc Bis(aminoalkylsulfamoyl) anthraquinones
US3829578A (en) * 1970-12-10 1974-08-13 Richardson Merrell Inc Antiviral compositions containing bis-basic ethers and thioethers of xanthene and xanthen-9-ones and methods of treating viruses therewith
US3714194A (en) * 1971-06-09 1973-01-30 Upjohn Co Di(azidosulfonyl)xanthones
US3919211A (en) * 1973-02-12 1975-11-11 American Home Prod 9-Oxoxanthene-N,N{40 -bis(substituted)-2,7-disulfonamides
US3981248A (en) * 1975-02-28 1976-09-21 Hall Ski-Lift Company, Inc. Timing gate for ski-lifts
US4250097A (en) * 1978-03-08 1981-02-10 Syntex (U.S.A.) Inc. Compositions for and a method of preventing diabetic complications
US4276224A (en) * 1978-06-07 1981-06-30 Ciba-Geigy Corporation Anthraquinone sulphonamide compounds and preparation
DE3044072A1 (de) * 1980-11-24 1982-07-15 Hoechst Ag, 6000 Frankfurt Bis-aminomehtyl-anthrachinon-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
IT1223302B (it) 1987-09-16 1990-09-19 Baldacci Lab Spa Composti solfonamido derivati inibitori del sistema enzimatico aldoso-reduttasi e composizioni farmaceutiche che li contengono
HUT67314A (en) * 1993-04-09 1995-03-28 Egyt Gyogyszervegyeszeti Gyar Process for prepg. new trisubstituted cykloalkane deriv.s and pharmaceutical compn.s contg. them
US7160896B2 (en) * 2000-07-07 2007-01-09 Cancer Research Technology Limited Therapeutic acridone and acridine compounds
WO2002011574A1 (en) * 2000-08-10 2002-02-14 Benetton Group S.P.A. Sports shoe
PL370449A1 (en) * 2002-01-15 2005-05-30 Cancer Research Technology Limited Therapeutic acridone and acridine compounds
US6693136B1 (en) * 2002-07-26 2004-02-17 Abbott Laboratories Fluorenes and anthracenes that inhibit P2X3 and P2X2/3 containing receptors
WO2006113097A2 (en) * 2005-04-15 2006-10-26 The University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
KR101486026B1 (ko) * 2007-05-10 2015-01-22 도그우드 파마슈티컬스, 아이엔씨. 플루오렌, 안트라센, 잔텐, 디벤조수베론 및 아크리딘의 유도체 및 이의 용도

Also Published As

Publication number Publication date
US20150313873A1 (en) 2015-11-05
KR101486026B1 (ko) 2015-01-22
CA2686402C (en) 2015-04-28
IL202039A0 (en) 2010-06-16
IL236827A (en) 2017-11-30
ZA200907859B (en) 2012-01-25
JP5782586B2 (ja) 2015-09-24
MX2009011970A (es) 2010-02-12
CA2871493A1 (en) 2008-11-20
US8129519B2 (en) 2012-03-06
US9120754B2 (en) 2015-09-01
CA2871493C (en) 2017-03-28
US20120129837A1 (en) 2012-05-24
JP2014193863A (ja) 2014-10-09
EP2152258B1 (en) 2016-05-04
NZ581647A (en) 2012-02-24
US20100137354A1 (en) 2010-06-03
HUE029155T2 (hu) 2017-02-28
JP6352017B2 (ja) 2018-07-04
AU2008251800B2 (en) 2014-07-10
AU2008251800A1 (en) 2008-11-20
NZ597731A (en) 2013-08-30
KR20100017768A (ko) 2010-02-16
PL2152258T3 (pl) 2017-09-29
CN101730531A (zh) 2010-06-09
CN108314663B (zh) 2022-05-13
US9446021B2 (en) 2016-09-20
CA2686402A1 (en) 2008-11-20
DK2152258T3 (en) 2016-08-22
IL202039A (en) 2015-02-26
PT2152258T (pt) 2016-08-18
WO2008140792A1 (en) 2008-11-20
EP2152258A4 (en) 2011-09-21
ES2584188T3 (es) 2016-09-26
JP2010526813A (ja) 2010-08-05
CN108314663A (zh) 2018-07-24
EP2152258A1 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
MX2009011970A (es) Derivados de fluoreno, antraceno, xanteno, dibenzosuberona y acridina y usos de ellos.
ECSP10010197A (es) Derivados de piridina y pirazina útiles en el tratamiento de trastornos de proliferación celular
ZA202308118B (en) Cdk inhibitor
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
MX2009009117A (es) Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
CO6781467A2 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
CO6390107A2 (es) Derivados de pirimidin indol para el tratamiento de cáncer.
TW200621729A (en) Pyrimidine derivatives
NO20083691L (no) Quinolin derivater
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
UY30759A1 (es) Compuestos quimicos
NO20090251L (no) Camptotecinderivater med antitumoraktivitet
UY28271A1 (es) Compuestos químicos
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
WO2007098086A3 (en) Hydroxypiperidine derivatives and uses thereof
MX2009013501A (es) Compuestos piperidinicos y sus usos.
WO2006001956A3 (en) Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
WO2005016264A3 (en) Diamine derivatives of quinone and uses thereof
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
MX359210B (es) Composición de combinación de pac-1 y tamoxifeno.
IL209270A (en) Compounds containing tricyclic nitrogen and their use as antibacterial
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
IL174787A0 (en) Use of cell lines to produce active therapeutic proteins
CA2865983A1 (en) Potent anticancer activity via dual compound activation